Summary
Urinary Tract Infection (UTI) is the most common infectious disease seen in humans. Also, UTI ranks as the Number 1 infection that leads to a prescription of antibiotics. Just in 2019, 404,6 million different UTI cases emerged worldwide that costed tens of billions of euros to economies and caused around 236.000 deaths. Luckily, UTIs can be cured effectively with right treatment. The problems need to be resolved are: diagnosing of UTI takes a long time (2-7 days), requires expertise and is costly; high false positive rates and contamination risk causes unnecessary laboratory costs and workload; empirical treatment given without waiting for long culture results leads to unnecessary and/or wrong antibiotic usage and consequently to antibiotic resistance.
As Nanomed Diagnostic, we developed an immunoassay-based point of care test kit for rapid, inexpensive and effortless detection of UTIs (RAPID UTI). It can diagnose UTI just in 5 minutes. It provides at least 10 times less cost for diagnosis by eliminating several technical processes and costly equipment and consumable investments. It eliminates all unnecessary laboratory costs and workload caused by false-positives and contaminated samples. It prevents unnecessary or wrong antibiotic usage and the bacteria to develop resistance to antibiotics.
Within the scope of the 12-month planned project, meetings will be held with European potential customers and distributors, samples will be sent, improvements will be made according to the feedback received, certification studies will be completed, product promotion will be made by participating in fairs, exhibitions and conferences, printed and digital marketing materials will be prepared, and a clinical trial will be conducted in an EU origin institution.
As Nanomed Diagnostic, we developed an immunoassay-based point of care test kit for rapid, inexpensive and effortless detection of UTIs (RAPID UTI). It can diagnose UTI just in 5 minutes. It provides at least 10 times less cost for diagnosis by eliminating several technical processes and costly equipment and consumable investments. It eliminates all unnecessary laboratory costs and workload caused by false-positives and contaminated samples. It prevents unnecessary or wrong antibiotic usage and the bacteria to develop resistance to antibiotics.
Within the scope of the 12-month planned project, meetings will be held with European potential customers and distributors, samples will be sent, improvements will be made according to the feedback received, certification studies will be completed, product promotion will be made by participating in fairs, exhibitions and conferences, printed and digital marketing materials will be prepared, and a clinical trial will be conducted in an EU origin institution.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101114063 |
| Start date: | 01-07-2023 |
| End date: | 30-06-2024 |
| Total budget - Public funding: | - 75 000,00 Euro |
Cordis data
Original description
Urinary Tract Infection (UTI) is the most common infectious disease seen in humans. Also, UTI ranks as the Number 1 infection that leads to a prescription of antibiotics. Just in 2019, 404,6 million different UTI cases emerged worldwide that costed tens of billions of euros to economies and caused around 236.000 deaths. Luckily, UTIs can be cured effectively with right treatment. The problems need to be resolved are: diagnosing of UTI takes a long time (2-7 days), requires expertise and is costly; high false positive rates and contamination risk causes unnecessary laboratory costs and workload; empirical treatment given without waiting for long culture results leads to unnecessary and/or wrong antibiotic usage and consequently to antibiotic resistance.As Nanomed Diagnostic, we developed an immunoassay-based point of care test kit for rapid, inexpensive and effortless detection of UTIs (RAPID UTI). It can diagnose UTI just in 5 minutes. It provides at least 10 times less cost for diagnosis by eliminating several technical processes and costly equipment and consumable investments. It eliminates all unnecessary laboratory costs and workload caused by false-positives and contaminated samples. It prevents unnecessary or wrong antibiotic usage and the bacteria to develop resistance to antibiotics.
Within the scope of the 12-month planned project, meetings will be held with European potential customers and distributors, samples will be sent, improvements will be made according to the feedback received, certification studies will be completed, product promotion will be made by participating in fairs, exhibitions and conferences, printed and digital marketing materials will be prepared, and a clinical trial will be conducted in an EU origin institution.
Status
SIGNEDCall topic
HORIZON-EIE-2022-SCALEUP-02-02Update Date
31-07-2023
Images
No images available.
Geographical location(s)
Search
